BioCryst Pharmaceuticals, Inc. (BCRX) stock analysis

BCRX · BioCryst Pharmaceuticals, Inc.

Latest recorded price: USD 7.45

Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic

Fiscal 2017 figures: revenue growth 22.8%, free cash flow margin -164.7%, ROIC -43.5%. The model flags 2 risk signals for this company (2 high severity).

Similar companies in Healthcare